SUPPLEMENT

Q2 2020 — Non-GAAP reconciliations

Q2 2020PDF · 9 pages273 KB
Adjusted Diluted Net Earnings Per Common Share from Continuing Operations 1
July 3, 2020 	June 28, 2019 	July 3, 2020 	June 28, 2019
1.24	$ 	0.90	$ 	2.06	$ 	1.36	$
Pretax amortization of acquisition-related intangible assets A
0.43 	0.21 	0.65 	0.43
Pretax acquisition-related fair value adjustments to inventory and deferred revenue,
incremental transaction costs deemed significant and integration preparation costs, in each case
related to the acquisition of Cytiva B
	0.31 	0.03 	0.39 	0.05
Pretax impairment charges related to a facility in the Diagnostics segment and a trade name
and other intangible assets in the Environmental & Applied Solutions segment C
- 	- 	0.01 	-
Pretax fair value adjustments and losses on the Company's equity and limited partnership
investments D
	0.01 	- 	0.02 	-
Gain on the sale of certain product lines in the Life Sciences segment in the second quarter of
2020 E
	(0.62) 	- 	(0.62) 	-
Tax effect of all adjustments reflected above F
0.05 	(0.04) 	- 	(0.09)
Discrete tax adjustments and other tax-related adjustments G
- 	(0.02) 	(0.04) 	0.31
Declared dividends on the MCPS assuming “if-converted” method H
0.02 	0.01 	0.03 	0.02
1.44	$ 	1.09	$ 	2.50	$ 	2.08	$
1
Adjusted Diluted Shares Outstanding
(shares in millions) 	July 3, 2020 	June 28, 2019 	July 3, 2020 	June 28, 2019
Average common stock and common equivalent shares outstanding - diluted 	718.2 	727.9 	713.1 	723.2
Converted shares 2 	16.8 	11.9 	14.6 	8.1
Adjusted average common stock and common equivalent shares outstanding - diluted 	735.0 	739.8 	727.7 	731.3
2
Core Sales Growth and Core Sales Growth Including Cytiva
% Change Three-Month
Period Ended July 3,
2020 vs. Comparable
2019 Period
% Change Six-Month
Period Ended July 3,
2020 vs. Comparable
2019 Period
Total sales growth (GAAP) 	19.0% 	11.5%
Impact of:
Acquisitions/divestitures 	(21.5%) 	(11.0%)
Currency exchange rates 	2.0% 	1.5%
Core sales growth (decline) (non-GAAP) 	(0.5%) 	2.0%
Impact of Cytiva sales growth (net of divested product lines) 	4.0% 	2.0%
Core sales growth including Cytiva (non-GAAP) 	3.5% 	4.0%
Forecasted Core Sales Growth and Core Sales Growth Including Cytiva
% Change Three-Month
Period Ending October
2, 2020 vs. Comparable
2019 Period
Core sales growth (non-GAAP) 	+Low- to mid-single digit
Impact of Cytiva sales growth (net of divested product lines) 	~300-400 bps
Core sales growth including Cytiva (non-GAAP) 	+Mid- to high-single digit
DANAHER CORPORATION
Each of the per share adjustment amounts above have been calculated assuming the Mandatory Convertible Preferred Stock (“MCPS”) had been converted into shares of common stock.
Three-Month Period Ended
Diluted Net Earnings Per Common Share from Continuing Operations (GAAP)
Adjusted Diluted Net Earnings Per Common Share from Continuing Operations (Non-
GAAP)
Three-Month Period Ended
Six-Month Period Ended
Six-Month Period Ended
The number of converted shares assumes the conversion of all MCPS and issuance of the underlying shares applying the “if-converted” method of accounting and using an average 20 trading-day trailing volume
weighted average price (“VWAP”) of $172.83 and $139.04 as of July 3, 2020 and June 28, 2019, respectively.
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
See the accompanying Notes to Reconciliation of GAAP to Non-GAAP Financial Measures

-- 1 of 9 --

Reconciliation of Operating Cash Flows from Continuing Operations (GAAP) to Free Cash Flow from Continuing Operations (Non-GAAP)
July 3, 2020 	June 28, 2019
Cash Flows from (used in) Continuing Operations ($ in millions):
Operating Cash Flows from Continuing Operations (GAAP) 	1,445.0	$ 	1,056.4	$
Investing Cash Flows from (used in) Continuing Operations (GAAP) 	539.3	$ 	(202.3)	$
Financing Cash Flows (used in) from Continuing Operations (GAAP) 	(888.0)	$ 	605.0	$
Free Cash Flow from Continuing Operations ($ in millions):
Operating Cash Flows from Continuing Operations (GAAP) 	1,445.0	$ 	1,056.4	$ 	~ 37.0%
Less: payments for additions to property, plant & equipment (capital expenditures) from
continuing operations (GAAP) 	(155.4) 	(154.3)
Plus: proceeds from sales of property, plant & equipment (capital disposals) from continuing
operations (GAAP) 	0.3 	11.2
Free Cash Flow from Continuing Operations (Non-GAAP) 	1,289.9	$ 	913.3	$ 	~ 41.0%
Ratio of Free Cash Flow from Continuing Operations to Net Earnings from Continuing
Operations ($ in millions):
Free Cash Flow from Continuing Operations from Above (Non-GAAP) 	1,289.9	$ 	913.3	$
Net Earnings from Continuing Operations (GAAP) 	927.3 	676.4
Free Cash Flow from Continuing Operations to Net Earnings from Continuing Operations
Conversion Ratio (Non-GAAP) 	1.39 	1.35
We define free cash flow as operating cash flows from continuing operations, less payments for additions to property, plant and equipment from continuing operations (“capital expenditures”) plus the proceeds from
sales of plant, property and equipment from continuing operations (“capital disposals”).
See the accompanying Notes to Reconciliation of GAAP to Non-GAAP Financial Measures
Three-Month Period Ended 	Year-over-Year
Change
DANAHER CORPORATION
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
(continued)

-- 2 of 9 --

A
July 3, 2020 	June 28, 2019 	July 3, 2020 	June 28, 2019
Pretax 	$ 	314.1 	$ 	156.3 	$ 	470.5 	$ 	313.7
After-tax 	252.9 	126.1 	378.8 	252.9
B
C
D
E
F
G
H
DANAHER CORPORATION
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
(continued)
Amortization of acquisition-related intangible assets in the following historical periods ($ in millions) (only the pretax amounts set forth below are reflected
in the amortization line item above):
Three-Month Period Ended
Notes to Reconciliation of GAAP to Non-GAAP Financial Measures
Six-Month Period Ended
Pretax fair value adjustments and losses on the Company's equity and limited partnership investments recorded in the three and six-month periods ended
July 3, 2020 ($6 million pretax as reported in this line item, $4 million after-tax and $13 million pretax as reported in this line item, $10 million after-tax,
respectively).
This line item reflects the aggregate tax effect of all nontax adjustments reflected in the preceding line items of the table. In addition, the footnotes above
indicate the after-tax amount of each individual adjustment item. Danaher estimates the tax effect of each adjustment item by applying Danaher’s overall
estimated effective tax rate to the pretax amount, unless the nature of the item and/or the tax jurisdiction in which the item has been recorded requires
application of a specific tax rate or tax treatment, in which case the tax effect of such item is estimated by applying such specific tax rate or tax treatment.
The MCPS dividends are not tax deductible and therefore the tax effect of the adjustments does not include any tax impact of the MCPS dividends.
Discrete tax adjustments and other tax-related adjustments for the six-month period ended July 3, 2020, include the impact of net discrete tax gains of $27
million (or $0.04 per diluted common share) related primarily to excess tax benefits from stock-based compensation and the release of reserves for uncertain
tax positions due to the expiration of statutes of limitation. Discrete tax adjustments and other tax-related adjustments for the three-month period ended
June 28, 2019 includes the impact of net discrete tax gains of $18 million or $0.02 per diluted common share. Discrete tax adjustments and other tax-
related adjustments for the six-month period ended June 28, 2019 includes the impact of net discrete tax charges of $227 million or $0.31 per diluted
common share. The discrete tax matters for the six-month period ended June 28, 2019 relate primarily to changes in estimates associated with prior period
uncertain tax positions and audit settlements, net of the release of valuation allowances associated with certain foreign tax credits and tax benefits resulting
from a change in law and excess tax benefits from stock-based compensation realized in the three and six-month periods ended June 28, 2019 in excess of
anticipated levels. The Company anticipates excess tax benefits from stock compensation of approximately $7 million per quarter and therefore excludes
benefits in excess of this amount in the calculation of Adjusted Diluted Net Earnings Per Common Share from Continuing Operations.
In March 2019, the Company issued $1.65 billion in aggregate liquidation preference of 4.75% MCPS. In May 2020. the Company issued $1.72 billion in
aggregate liquidation preference of 5.0% MCPS. Dividends on the 4.75% and 5.0% MCPS are payable on a cumulative basis at an annual rate of 4.75%
and 5.0%, respectively, on the liquidation preference of $1,000 per share. Unless earlier converted, each share of 4.75% MCPS will automatically convert
on April 15, 2022 into between 6.6549 and 8.1522 shares of Danaher’s common stock, subject to further anti-dilution adjustments. Unless earlier
converted, each share of 5.0% MCPS will automatically convert on April 15, 2023 into between 5.0081 and 6.1349 shares of Danaher’s common stock,
subject to further anti-dilution adjustments. The number of shares of Danaher’s common stock issuable on conversion of the MCPS will be determined
based on the VWAP per share of the Company's common stock over the 20 consecutive trading day period beginning on, and including, the 21st scheduled
trading day immediately before April 15, 2022 and April 15, 2023 for the 4.75% and 5.0% MCPS, respectively. For the purposes of calculating adjusted
earnings per share, the Company has excluded the paid and anticipated MCPS cash dividends and assumed the “if-converted” method of share dilution (the
incremental shares of common stock deemed outstanding applying the “if-converted” method of calculating share dilution are referred to as the “Converted
Shares”.)
Pretax impairment charges related to a facility in the Diagnostics segment and a trade name and other intangible assets in the Environmental & Applied
Solutions segment recorded in the six-month period ended July 3, 2020 ($8 million pretax as reported in this line item, $6 million after-tax).
Pretax costs incurred for fair value adjustments to inventory and deferred revenue related to the Cytiva Acquisition in the three-month period ended July 3,
2020 ($228 million pretax as reported in this line item, $178 million after-tax) and fair value adjustments to inventory and deferred revenue, transaction
costs deemed significant and integration preparation costs related to the Cytiva Acquisition for the six-month period ended July 3, 2020 ($288 million
pretax as reported in this line item, $231 million after-tax). Pretax costs incurred for transaction costs deemed significant and integration preparation costs
related to the Cytiva Acquisition for the three-month period ended June 28, 2019 ($18 million pretax as reported in this line item, $16 million after-tax) and
the six-month period ended June 28, 2019 ($33 million pretax as reported in this line item, $29 million after-tax). The Company deems acquisition-related
transaction costs incurred in a given period to be significant (generally relating to the Company’s larger acquisitions) if it determines that such costs exceed
the range of acquisition-related transaction costs typical for Danaher in a given period.
Pretax gain on the sale of certain product lines in the Life Sciences segment in the three and six-month periods ended July 3, 2020 ($455 million pretax as
reported in this line item, $305 million after-tax).

-- 3 of 9 --

Statement Regarding Non-GAAP Measures
•
•
•
The items excluded from the non-GAAP measures set forth above have been excluded for the following reasons:
•
o
o
o
o
We exclude the amortization of acquisition-related intangible assets because the amount and timing of such charges
are significantly impacted by the timing, size, number and nature of the acquisitions we consummate. While we
have a history of significant acquisition activity we do not acquire businesses on a predictable cycle, and the amount
of an acquisition’s purchase price allocated to intangible assets and related amortization term are unique to each
acquisition and can vary significantly from acquisition to acquisition. Exclusion of this amortization expense
facilitates more consistent comparisons of operating results over time between our newly acquired and long-held
businesses, and with both acquisitive and non-acquisitive peer companies. We believe however that it is important
for investors to understand that such intangible assets contribute to sales generation and that intangible asset
amortization related to past acquisitions will recur in future periods until such intangible assets have been fully
amortized.
We exclude costs incurred pursuant to discrete restructuring plans that are fundamentally different (in terms of the
size, strategic nature and planning requirements, as well as the inconsistent frequency, of such plans) from the
ongoing productivity improvements that result from application of the Danaher Business System. Because these
restructuring plans are incremental to the core activities that arise in the ordinary course of our business and we
believe are not indicative of Danaher’s ongoing operating costs in a given period, we exclude these costs to facilitate
a more consistent comparison of operating results over time.
With respect to the other items excluded from Adjusted Diluted Net Earnings Per Common Share from Continuing
Operations, we exclude these items because they are of a nature and/or size that occur with inconsistent frequency,
occur for reasons that may be unrelated to Danaher's commercial performance during the period and/or we believe
that such items may obscure underlying business trends and make comparisons of long-term performance difficult.
Danaher’s Mandatory Convertible Preferred Stock (“MCPS”) will mandatorily convert into Danaher common stock
on the mandatory conversion date, which is expected to be April 15, 2022 and April 15, 2023 for the 4.75% and
5.0% MCPS, respectively, (unless converted or redeemed earlier in accordance with the terms of the applicable
certificate of designations). On the prior pages, we present the earnings per share-related measures on a basis which
assumes the MCPS had already been converted as of the beginning of the applicable period (and accordingly also
exclude the dividends that were actually paid on the MCPS during such period, since such dividends would no
longer be paid once the MCPS convert). We believe this presentation provides useful information to investors by
helping them understand what the net impact will be on Danaher’s earnings per share-related measures once the
MCPS convert into Danaher common stock.
with respect to free cash flow (the “FCF Measure”), understand Danaher’s ability to generate cash without external financings, strengthen
its balance sheet, invest in its business and grow its business through acquisitions and other strategic opportunities (although a limitation
of free cash flow is that it does not take into account the Company’s debt service requirements and other non-discretionary expenditures,
and as a result the entire free cash flow amount is not necessarily available for discretionary expenditures).
With respect to Adjusted Diluted Net Earnings Per Common Share from Continuing Operations:
Each of the non-GAAP measures set forth above should be considered in addition to, and not as a replacement for or superior to, the comparable GAAP
measure, and may not be comparable to similarly titled measures reported by other companies. Management believes that these measures provide useful
information to investors by offering additional ways of viewing Danaher Corporation’s (“Danaher” or the “Company”) results that, when reconciled to the
corresponding GAAP measure, help our investors to:
Management uses these non-GAAP measures to measure the Company’s operating and financial performance, and uses core sales and non-GAAP measures
similar to Adjusted Diluted Net Earnings Per Common Share from Continuing Operations and the FCF Measure in the Company’s executive compensation
program.
with respect to Adjusted Diluted Net Earnings Per Common Share from Continuing Operations, understand the long-term profitability
trends of our business and compare our profitability to prior and future periods and to our peers;
with respect to core sales from continuing operations, identify underlying growth trends in our business and compare our sales
performance with prior and future periods and to our peers; and
We also present core sales from continuing operations on a basis that includes sales attributable to Cytiva (formerly the Biopharma Business of General
Electric Company’s (“GE”) Life Sciences business), which Danaher acquired from GE on March 31, 2020. Historically Danaher has calculated core sales
solely on a basis that excludes sales from acquired businesses recorded prior to the first anniversary of the acquisition. However, given Cytiva’s significant
size and historical core sales growth rate, in each case compared to Danaher’s existing businesses, management believes it is appropriate to also present core
sales on a basis that includes Cytiva sales. Management believes this presentation provides useful information to investors by demonstrating the impact
Cytiva has on the Company’s current growth profile, rather than waiting to demonstrate such impact 12 months after the acquisition when Cytiva would
normally have been included in Danaher’s core sales calculation. Danaher calculates period-to-period core sales growth including Cytiva by adding to the
baseline period sales Cytiva’s historical sales from such period (when it was owned by GE), net of the sales of the divested product lines and also adding the
Cytiva sales to the current period.

-- 4 of 9 --

•
• With respect to the FCF Measure, we exclude payments for additions to property, plant and equipment (net of the proceeds from capital
disposals) to demonstrate the amount of operating cash flow for the period that remains after accounting for the Company’s capital
expenditure requirements.
With respect to core sales from continuing operations and core sales from continuing operations including Cytiva, (1) we exclude the
impact of currency translation because it is not under management’s control, is subject to volatility and can obscure underlying business
trends, and (2) we exclude the effect of acquisitions (other than Cytiva, in the case of core sales from continuing operations including
Cytiva) and divested product lines because the timing, size, number and nature of such transactions can vary significantly from period-to-
period and between us and our peers, which we believe may obscure underlying business trends and make comparisons of long-term
performance difficult.
With respect to forecasted core sales from continuing operations and forecasted core sales from continuing operations including Cytiva, we do not reconcile
these measures to the comparable GAAP measure because of the inherent difficulty in predicting and estimating the future impact and timing of currency
translation, acquisitions and divested product lines, which would be reflected in any forecasted GAAP revenue.

-- 5 of 9 --

Reconciliation of Operating Cash Flows from Continuing Operations (GAAP) to Free Cash Flow from Continuing Operations (Non-GAAP)
April 3,
2020
March 29,
2019
July 3,
2020
June 28,
2019
July 3,
2020
June 28,
2019
Cash Flows from Continuing Operations ($ in millions):
Operating Cash Flows from Continuing Operations (GAAP) 	826.0	$ 	712.7	$ 	1,445.0	$ 	1,056.4	$ 	2,271.0	$ 	1,769.1	$
Investing Cash Flows from Continuing Operations (GAAP) 	(20,868.6)	$ 	(483.2)	$ 	539.3	$ 	(202.3)	$ 	(20,329.3)	$ 	(685.5)	$
Financing Cash Flows from Continuing Operations (GAAP) 	4,633.5	$ 	2,877.8	$ 	(888.0)	$ 	605.0	$ 	3,745.5	$ 	3,482.8	$
Free Cash Flow from Continuing Operations ($ in millions):
Operating Cash Flows from Continuing Operations (GAAP) 	826.0	$ 	712.7	$ 	1,445.0	$ 	1,056.4	$ 	≈ 37.0% 	2,271.0	$ 	1,769.1	$ 	≈ 28.5%
Less: payments for additions to property, plant & equipment (capital expenditures) from
continuing operations (GAAP) 	(132.5) 	(140.1) 	(155.4) 	(154.3) 	(287.9) 	(294.4)
Plus: proceeds from sales of property, plant & equipment (capital disposals) from continuing
operations (GAAP) 	0.5 	0.5 	0.3 	11.2 	0.8 	11.7
Free Cash Flow from Continuing Operations (Non-GAAP) 	694.0	$ 	573.1	$ 	1,289.9	$ 	913.3	$ 	≈ 41.0% 	1,983.9	$ 	1,486.4	$ 	≈ 33.5%
Ratio of Free Cash Flow from Continuing Operations to Net Earnings from Continuing
Operations ($ in millions):
Free Cash Flow from Continuing Operations from Above (Non-GAAP) 	694.0	$ 	573.1	$ 	1,289.9	$ 	913.3	$ 	1,983.9	$ 	1,486.4	$
Net Earnings from Continuing Operations (GAAP) 	595.1 	332.3 	927.3 	676.4 	1,522.4 	1,008.7
Free Cash Flow from Continuing Operations to Net Earnings from Continuing Operations
Conversion Ratio (Non-GAAP) 	1.17 	1.72 	1.39 	1.35 	1.30 	1.47
We define free cash flow as operating cash flows from continuing operations, less payments for additions to property, plant and equipment from continuing operations (“capital expenditures”) plus the proceeds from sales of plant, property and equipment
from continuing operations (“capital disposals”).
DANAHER CORPORATION
Three-Month Period Ended 	Three-Month Period Ended 	Six-Month Period Ended
Year-over-
Year Change
Year-over-
Year Change

-- 6 of 9 --

Year-Over-Year Core Operating Margin Changes From Continuing Operations
Total Company 	Life Sciences 	Diagnostics
Environmental &
Applied Solutions
18.30% 	20.10% 	17.50% 	23.40%
Second quarter 2020 impact from operating profit margins of
businesses that have been owned for less than one year or were
disposed of during such period and did not qualify as
discontinued operations 	2.40 	3.85 	- 	-
Second quarter 2020 acquisition-related fair value
adjustments to inventory and deferred revenue and incremental
transaction costs deemed significant, in each case related to the
acquisition of Cytiva 	(4.00) 	(8.65) 	- 	-
(0.80) 	0.30 	0.20 	(1.10)
15.90% 	15.60% 	17.70% 	22.30%
17.70% 	19.60% 	16.40% 	23.30%
First half of 2020 impact from operating profit margins of
businesses that have been owned for less than one year or were
disposed of during such period and did not qualify as
discontinued operations 	1.40 	2.35 	- 	-
First half of 2020 acquisition-related fair value adjustments to
inventory and deferred revenue, incremental transaction costs
deemed significant and integration preparation costs, in each
case related to the acquisition of Cytiva 	(2.65) 	(5.35) 	- 	-
First quarter 2020 impairment charges related to a facility in the
Diagnostics segment and a trade name and other intangible
assets in the Environmental & Applied Solutions segment 	(0.10) 	- 	(0.15) 	(0.20)
(0.35) 	0.60 	0.35 	(0.70)
16.00% 	17.20% 	16.60% 	22.40%
Note: The Company deems acquisition-related transaction costs incurred in a given period to be significant (generally relating to the Company’s larger acquisitions) if it
determines that such costs exceed the range of acquisition-related transaction costs typical for Danaher in a given period.
DANAHER CORPORATION
Three-Month Period Ended June 28, 2019 Operating Profit
Margins From Continuing Operations (GAAP)
Three-Month Period Ended July 3, 2020 Operating Profit Margins
From Continuing Operations (GAAP)
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
Segments
Year-over-year core operating profit margin changes for the
second quarter 2020 (defined as all year-over-year operating
profit margin changes other than the changes identified in the line
items above) (non-GAAP)
Six-Month Period Ended June 28, 2019 Operating Profit Margins
From Continuing Operations (GAAP)
Six-Month Period Ended July 3, 2020 Operating Profit Margins From
Continuing Operations (GAAP)
Year-over-year core operating profit margin changes for first
quarter 2020 (defined as all year-over-year operating profit
margin changes other than the changes identified in the line items
above) (non-GAAP)

-- 7 of 9 --

Danaher Corporation
Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures
($ in Millions)
Year-over-Year Adjusted Operating Margin Change (1)
July 3, 2020 	June 29, 2019 	Change
Operating Profit (GAAP) 	844.6	$ 	811.7	$
Sales (GAAP) 	5,297.4 	4,444.5
Operating Profit Margin (GAAP) 	15.9% 	18.3% 	(240 bps)
Second quarter 2020 impact of acquisition-related fair value adjustments to
inventory and deferred revenue, in each case related to the acquisition of Cytiva ~ 400 bps
Year-over-year Adjusted Operating Margin Change (Non-GAAP) (1) 	> 150 bps
Year-over-Year Adjusted Gross Margin Change (1)
July 3, 2020 	June 29, 2019 	Change
Gross Profit (GAAP) 	2,852.6	$ 	2,483.8	$
Sales (GAAP) 	5,297.4 	4,444.5
Gross Margin (GAAP) 	53.8% 	55.9% 	(210 bps)
Second quarter 2020 impact of acquisition-related fair value adjustments to
inventory and deferred revenue, in each case related to the acquisition of Cytiva ~ 400 bps
Year-over-year Adjusted Gross Margin Change (Non-GAAP)(1) 	> 150 bps
Three-Month Period Ended
Three-Month Period Ended
(1) Management defines "Adjusted Operating Margin Change " as GAAP operating margin excluding acquisition-related fair value adjustments to
inventory and deferred revenue, in each case related to the acquisition of Cytiva and defines "Adjusted Gross Margin Change" as GAAP Gross
Margin excluding acquisition-related fair value adjustments to inventory and deferred revenue, in each case related to the acquisition of Cytiva.

-- 8 of 9 --

Core Sales Growth and Core Sales Growth Including Cytiva
Total Company 	Life Sciences
Total sales growth (GAAP) 	19.0% 	54.5%
Impact of:
Acquisitions/divestitures 	(21.5%) 	(55.5%)
Currency exchange rates 	2.0% 	1.0%
Core sales growth (decline) (non-GAAP) 	(0.5%) 	--%
Impact of Cytiva sales growth (net of divested product lines) 	4.0% 	8.0%
Core sales growth including Cytiva (non-GAAP) 	3.5% 	8.0%
Core Sales Growth
Diagnostics
Environmental &
Applied Solutions
Total sales growth (GAAP) 	2.5% 	(10.5%)
Impact of:
Currency exchange rates 	2.5% 	2.0%
Core sales growth (decline) (non-GAAP) 	5.0% 	(8.5%)
DANAHER CORPORATION
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
% Change Three-Month Period Ended July 3, 2020
vs. Comparable 2019 Period
% Change Three-Month Period Ended July 3, 2020
vs. Comparable 2019 Period

-- 9 of 9 --